Youn Kim

Youn Kim is a preeminent expert on cutaneous T-cell lymphoma who led the pivotal MAVORIC trial demonstrating superiority of mogamulizumab over vorinostat in relapsed mycosis fungoides and Sezary syndrome, establishing a new standard of care. She has contributed foundational work on staging, biomarkers, and clinical outcomes in MF/SS and serves on ISCL (International Society for Cutaneous Lymphomas) leadership. Her career spans over three decades of CTCL clinical and translational research.